ArticleBlood advances2025
STAT1-mediated epigenetic regulation of LIN28A controls iPSC-derived platelet production through the let-7-RALB axis.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Induced pluripotent stem cell-derived platelets kill multidrug-resistantResearch and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractEx vivo platelet (PLT) production from induced pluripotent stem cells (iPSCs) represents a potential solution to address the limitations of donor-dependent PLT transfusion therapy. Although our established immortalized megakaryocyte progenitor cell lines (imMKCLs) from iPSCs enable large-scale production of functional iPSC-derived PLT products, cellular heterogeneity and senescence remain significant challenges for robust industrial-scale manufacturing. We recently identified RAS-like proto-oncogene B as a key regulator of immune properties and PLT productivity of imMKCLs, acting downstream of the let-7a-5p microRNA. This study aims to identify the upstream regulators of let-7a-5p in this context. Herein, we demonstrate that the expression of Lin-28 homolog A (LIN28A), which negatively regulates let-7a-5p, is controlled in imMKCLs through DNA methylation-dependent mechanisms. Analysis of the LIN28A locus revealed distinct methylation patterns between let-7high and let-7low populations within an intronic CpG island. Overexpression of LIN28A upregulated immune-related signaling and diminished PLT production from imMKCLs. We further examined for transcriptional regulators by motif enrichment analysis and small interfering RNA-mediated knockdown, identifying STAT1 as an upstream regulator of LIN28A. Knockdown of STAT1 led to the suppression of immune-related gene expression, resulting in increased PLT production. Inhibition of STAT1 phosphorylation with fludarabine and flavopiridol enhanced PLT generation, uncovering a novel role in PLT generation beyond their established functions in cell cycle arrest and apoptosis. In conclusion, our findings unveil the modulating roles of immune and senescence signaling in imMKCLs to optimize cell and culture conditions for large-scale PLT manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.